LIVE NCPD WEBINARS: June 10 and Aug 5, 2021

Summer Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Chronic Lymphocytic Leukemia

Register Now

Register for these complimentary events with the “Register Now ” button above,
which will take you to our Zoom registration page.

All events moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Thursday, June 10, 2021, 5:00 PM – 6:00 PM ET

Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Kristen E Battiato, AGNP-C
Advanced Practice Providers
Memorial Sloan Kettering Cancer Center
New York, New York

 

Thursday, August 5, 2021, 5:00 PM – 6:00 PM ET

John M Pagel, MD, PhD
Chief of Hematologic Malignancies Program
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington
Lesley Camille Ballance, MSN, FNP-BC
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

 

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Topics to Be Discussed

  • Overview of chronic lymphocytic leukemia (CLL) incidence and prognosis, patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting patient care
  • Role of cytogenetics and molecular profiling in prognostication, risk stratification and treatment decision-making for CLL; 17p deletion, TP53 and IGHV gene mutations
  • Mechanism of action, effectiveness and incorporation into therapy of the approved Bruton tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib, alone or in combination with an anti-CD20 antibody, for newly diagnosed or relapsed/refractory CLL; comparative tolerability profiles and management of side effects
  • Integration of the Bcl-2 inhibitor venetoclax in combination with an anti-CD20 antibody into therapy for newly diagnosed or relapsed/refractory CLL; risk of tumor lysis syndrome and preemptive measures, including dose ramp-up; role of minimal residual disease in determining treatment duration
  • Management of multiple regimen-relapsed CLL; mechanism of action, effectiveness and incorporation into therapy of the PI3K inhibitors idelalisib and duvelisib; common toxicities and mitigation of side effects
  • Novel agents under investigation for CLL, including the noncovalent BTK inhibitor LOXO-305; mechanism of action and potential clinical role
  • Efficacy of CAR T-cell therapy for patients with CLL in ongoing clinical trials; spectrum, incidence and management of associated adverse events

Target Audience
These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of each activity, participants should be able to

  • Apply available clinical information and research data to the therapeutic and supportive care of patients with CLL.
  • Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for patients with newly diagnosed CLL.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition with ibrutinib or acalabrutinib compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and discern how this strategy can be optimally integrated into nonresearch treatment.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how this regimen can be appropriately integrated into treatment decision-making.
  • Recognize how published research data, prior therapeutic exposure and the results of biomarker analyses can influence the selection and sequencing of therapy, and use this information to counsel patients with relapsed/refractory CLL about the rationale for individualized treatment recommendations.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with systemic therapies commonly used in the management of CLL, in order to support quality of life and continuation of therapy.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
Each educational activity for 1 contact hour is provided by RTP.

Each activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for each event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.researchtopractice.com/Webinars/ONS2021/MTP/CLL/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Ballance and Ms Battiato have no relevant conflicts of interest to disclose.The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr PagelConsulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Gilead Sciences Inc, MorphoSys, Seagen Inc. Dr WoyachAdvisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Consulting Agreements: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.